MotherToBaby

Medications and More during pregnancy and breastfeeding

866.626.6847

HPV Vaccine

Selected References:

  • American College of Obstetricians and Gynecologists. 2013. ACOG committee opinion no. 558: Integrating immunizations into practice. Obstet Gynecol 121(4):897-903.
  • Angelo MG, et al. 2014.Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme. Pharmacoepidemiol Drug Saf. 23(5):466-79. doi:10.1002/pds.3554.
  • Baril L, et al. 2015. Risk of spontaneous abortion and other pregnancy outcomes in 15-25 year old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom. Vaccine 33(48):6884-91.
  • Centers for Disease Control and Prevention. 2016. Guidelines for vaccinating pregnant women. Available at https://www.cdc.gov/vaccines/pubs/preg-guide.htm
  • Chen W, et al. 2019. Safety of a quadravalent human papillomavirus vaccine in a Phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90 months of follow-up. Vaccine 37(6):889-97. Doi.10.1016/j.vaccine.2018.12.030.
  • Cho G, et al. 2013. High-risk human papillomavirus infection is associated with premature rupture of membranes. BMC Pregnancy Childbirth 13:173.
  • Dana A, et al. 2009. Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet Gynecol.  114(6):1170-8.
  • Faber MT, et al 2019. Adverse pregnancy outcomes and infant mortality after quadravalent HPV vaccination during pregnancy. Vaccine 37,265-271,https://doi.org/10.1016/j.vaccine.2018.11.030.
  • Ford, J, et al. 2017. Human papillomavirus infection and intrauterine growth restriction: a data-linkage study. The Journal of Maternal-Fetal & Neonatal Medicine.
  • Garland SM, et al. 2009. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol 114(6):1179-1188.
  • Gomez LM, et al. 2008. Placental infection with human papillomavirus is associated with spontaneous preterm delivery. Hum Reprod 23(3):709-715.
  • Goss MA, et al. 2015. Final report on exposure during pregnancy from a pregnancy registry for quadrivalent human papillomavirus vaccine. Vaccine 33(29): 3422-3428.
  • Hahn HS, et al. 2013. Distribution of maternal and infant human papillomavirus: risk factors associated with vertical transmission. Eur J Obstet Gynecol Reprod Biol 169(2):202-6.
  • Hermonat PL, et al. 1997. Human papillomavirus is more prevalent in first trimester spontaneously aborted products of conception compared to elective specimens. Virus Genes 14(1):13-17
  • Hong Y, et al. 2013. Survey of human papillomavirus types and their vertical transmission in pregnant women. BMC Infect Dis 13:109
  • Kharbanda EO, et al. 2018. Risk of spontaneous abortion after inadvertent human papillomavirus vaccination in pregnancy. Obstet Gynecol 2018; 132:34-44.
  • Landazabal CS, et al. 2019. Safety of 9- valent human papillomavirus vaccine administration among pregnant women: Adverse event reports in the Vaccine Adverse Event Reporting System (VAERS), 2014-2017. Vaccine 37:1229-1234, https://doi.org/10.1016/j.vaccine.2018.11.077.
  • Lawton B, et al. 2018. Association of prior HPV vaccination with reduced preterm birth: a population based study. Vaccine 36; 134-140; https://doi.org/10.1016/j.vaccine.2017.11.020.
  • Lipkind HS, et al. 2017. Maternal and infant outcomes after human papillomavirus vaccination in the periconceptional period or during pregnancy. Obstet Gynecol; 130(3):599-608.
  • Markowitz LE, et al. 2007.Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 56 (RR-2):1-24. https://www.cdc.gov/mmwr/preview/mmwrhtml/rr56e312a1.htm
  • Matys K, et al. 2012. Mother-infant transfer of anti-human papillomavirus (HPV) antibodies following vaccination with the quadravalent HPV (type 6/11/16/18) virus-like particle vaccine. Clin Vaccine Immunol. Jun; 19(6):881-5. doi: 10.1128/CVI.00002-12. PMID: 22518014; PMCID: PMC3370453.
  • McDonnold M, et al. 2014. High risk human papillomavirus at entry to prenatal care and risk of preeclampsia. Am J Obstet Gynecol 210(2):138.e1-5.
  • Moreira ED, E et al. 2016. Safety profile of the 9-valent HPV vaccine: A combined analysis of 7 phase III clinical trials. Pediatrics. 138(2):e20154387.
  • Panagiotou OA, et al. 2015. Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial. BMJ 7; 351:h4358.
  • Segal L, et al. 2011. Evaluation of the intramuscular administration of Cervarix vaccine on fertility, pre- and post-natal development in rats. Reprod Toxicol 31(1):111-20.
  • Scheller NM, et al. 2017. Quadravalent HPV vaccination and the risk of adverse pregnancy outcomes. N Engl J Med; 376:1223-1233.
  • Subramaniam A, et al. 2016. Evaluation of human papillomavirus as a risk factor for preterm birth or pregnancy-related hypertension. Obstet Gynecol 127(2):233-240.
  • Wacholder S, et al. 2010. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomized clinical trials. BMJ 340:C712.
  • Winckworth LC and Nichol R. 2010. Question 2: do caesarean sections reduce the maternal-fetal transmission rate of human papillomavirus infection? Arch Dis Child 95(1):70-73.
  • Wise LD, et al. 2008. Lack of effects on fertility and developmental toxicity of a quadrivalent HPV vaccine in Sprague-Dawley rats. Birth Defects Res (B) 83:561-572.